Quantum Genomics: Current Situation and Financial Challenges

Quantum Genomics recently announced its status following the suspension of trading in its shares by Euronext effective October 25, 2024. This decision was prompted by an uncompleted reverse acquisition. The company is currently seeking a partner for a re-entry transaction, with a preference for the healthcare sector. However, no operational activities are underway.

Quantum Genomics' financial situation remains worrying. With cash of €150,000 as of April 4, 2025, the company has four months of financial visibility. A new round of fundraising is essential to avoid a potential liquidation. The 2024 annual accounts will be published no later than April 30, 2025.